Lido Advisors LLC Sells 5,350 Shares of Lantheus Holdings, Inc. $LNTH

Lido Advisors LLC lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 8.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 56,855 shares of the medical equipment provider’s stock after selling 5,350 shares during the period. Lido Advisors LLC owned approximately 0.09% of Lantheus worth $4,312,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its holdings in Lantheus by 190.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after purchasing an additional 698 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after buying an additional 19,008 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after buying an additional 500 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Lantheus by 88.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 1,591 shares during the period. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Lantheus in the second quarter valued at about $36,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LNTH. Mizuho raised their price target on shares of Lantheus from $115.00 to $120.00 and gave the stock a “market outperform” rating in a research report on Wednesday, July 15th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Finally, Truist Financial lifted their price target on shares of Lantheus from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.43.

Lantheus Stock Performance

LNTH opened at $104.82 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $111.86. The firm has a market cap of $6.82 billion, a P/E ratio of 25.26 and a beta of -0.06. The business’s fifty day moving average is $103.36 and its 200-day moving average is $85.56.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the previous year, the firm earned $1.53 earnings per share. Lantheus’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts expect that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.